New drug formulation helps prevent kidney stone recurrence

March 11, 2010

Mission Pharmacal Co. recently introduced a potassium citrate (Urocit-K 15 mEq) extended-release tablet for the prevention of kidney stone recurrence.

Mission Pharmacal Co. recently introduced a potassium citrate (Urocit-K 15 mEq) extended-release tablet for the prevention of kidney stone recurrence.

"The availability of Urocit-K 15 mEq is important for kidney stone patients because it can help ease their pill burden," said David S. Goldfarb, MD, of New York University Langone Medical Center and New York Harbor Veterans Affairs Medical Center. "Therefore, this new dosage regimen may help patients to comply with their treatment regimens and, ultimately, help keep new kidney stones from forming."

The product also features a slow-release wax-matrix delivery system that enhances a patient’s tolerability to take oral potassium citrate, which in turn, also helps increase patient compliance, according to Mission Pharmacal.